GCP
PTLA

GSA Capital Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

GSA Capital Partners’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,665
Closed -$541K – 1770
2019
Q4 		$541K Buy
22,665
+4,060
+22% +$112K 0.06% 599
2019
Q3 		$499K Buy
+18,605
New +$522K 0.07% 557
2015
Q3 		– Sell
-4,900
Closed -$223K – 2137
2015
Q2 		$223K Buy
+4,900
New +$197K 0.01% 1770

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

GSA Capital Partners's PTLA Position: Q1 2020 in Review

GSA Capital Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 22,665 shares — an estimated $541K sold.

GSA Capital Partners first reported a position in PTLA in Q2 2015 and held it in 3 quarters. The position peaked at $541K in Q4 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • GSA Capital Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • GSA Capital Partners sold 22,665 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $541K.
  • GSA Capital Partners first reported a position in Portola Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
  • GSA Capital Partners's Portola Pharmaceuticals, Inc. position peaked at $541K in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on GSA Capital Partners's 13F filing for Q1 2020, filed 12 May 2020.